Related Experiment Video
Updated: May 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Comparative effectiveness of antiviral therapies in chronic hepatitis B and C management
Ashis Tiwari1, Praveen Kumar Tagore1, Sukh Dayal Kumhar1
1Department of General Medicine, Government Medical College, Datia, Madhya Pradesh, India.
Abstract:
Chronic hepatitis B and C infections affect over 350 million people worldwide, leading to progressive liver disease that demands effective antiviral therapy. Hence, this study compares four antiviral regimens across 480 patients (4 groups of 120 each): tenofovir or entecavir for HBV and sofosbuvir-based or glecaprevir/pibrentasvir combinations for HCV over 48 weeks. Glecaprevir/pibrentasvir achieved superior HCV suppression (96.7% SVR versus 94.2% sofosbuvir-based, p=0.032), while HBV showed 100% tenofovir versus 87.8% entecavir suppression (p=0.421). Both drug classes demonstrated high efficacy in halting viral replication and minimizing progression to chronic liver damage. These results advance therapeutic knowledge by identifying glecaprevir/pibrentasvir as a marginally superior HCV regimen and reinforcing evidence-based antiviral selection for durable viral suppression.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test